Outcomes associated with under-dosing of rivaroxaban for management of non-valvular atrial fibrillation in real-world Japanese clinical settings

The approved dose of oral anticoagulant rivaroxaban for patients with non-valvular atrial fibrillation (NVAF) in Japan is 15 mg once daily (od) in patients whose creatinine clearance is ≥ 50 mL/min, but recent real-world studies have demonstrated that these patients often received less than the reco...

Descripción completa

Detalles Bibliográficos
Autores principales: Ikeda, Takanori, Ogawa, Satoshi, Kitazono, Takanari, Nakagawara, Jyoji, Minematsu, Kazuo, Miyamoto, Susumu, Murakawa, Yuji, Iwashiro, Sanghun, Kidani, Yoko, Okayama, Yutaka, Sunaya, Toshiyuki, Sato, Shoichiro, Yamanaka, Satoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6800859/
https://www.ncbi.nlm.nih.gov/pubmed/31432451
http://dx.doi.org/10.1007/s11239-019-01934-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6800859/
https://www.ncbi.nlm.nih.gov/pubmed/31432451
http://dx.doi.org/10.1007/s11239-019-01934-6

Ejemplares similares